<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397982</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00133</org_study_id>
    <secondary_id>NCI-2009-00133</secondary_id>
    <secondary_id>NCI-7190</secondary_id>
    <secondary_id>CDR0000512836</secondary_id>
    <secondary_id>UVACC-MEL-47</secondary_id>
    <secondary_id>MEL47</secondary_id>
    <secondary_id>7190</secondary_id>
    <secondary_id>P30CA044579</secondary_id>
    <secondary_id>R21CA128367</secondary_id>
    <nct_id>NCT00397982</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma</brief_title>
  <acronym>Mel47</acronym>
  <official_title>A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving temsirolimus together with bevacizumab works
      in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the
      growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal
      antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
      carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant
      melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab
      may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the objective tumor response rate (complete response and partial response) in
      patients with stage III or IV melanoma treated with temsirolimus and bevacizumab.

      SECONDARY OBJECTIVES:

      I. Describe the adverse event profile of this regimen in these patients. II. Determine the
      efficacy of this regimen, in terms of progression-free survival, in these patients.

      III. Compare pre- vs post-treatment measurements of biomarkers and vascular system/immune
      system parameters in patients treated with this regimen.

      IV. Correlate tumor and blood biomarkers with clinical response in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive temsirolimus intravenously (IV) over 30 minutes on days 1 and 8 and
      bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of
      26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo
      tumor resection on day 9 of course 2.Blood samples are collected during courses 1 and 2.
      Samples are examined by flow cytometry to evaluate peripheral blood mononuclear cells for
      molecular effects of study agents. Patients also undergo normal and tumor tissue biopsy (by
      core needle biopsy, incisional biopsy, or surgical resection) during courses 1 and 2. Samples
      are examined by immunohistochemistry, western blotting, protein array technology, gene
      expression analyses, DNA mutation analyses, and genomic analyses for pre-and post-treatment
      measurements of target molecules (epidermal growth factor receptor, B-Raf, MEK, MAPK),
      downstream pathway components (PI-3 kinase, AKT, mTOR), markers of angiogenesis,
      proliferation and apoptosis, markers that may modulate cell signaling or the response to
      investigational agents, and vascular and immune system parameters.

      After completion of study treatment, patients are followed at 1 month, every 3 months for up
      to 2 years, and then periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and Bevacizumab</measure>
    <time_frame>Up to 18 weeks after registration.</time_frame>
    <description>Evaluated using Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events in Participants With Stage III or IV Melanoma Treated With Temsirolimus and Bevacizumab</measure>
    <time_frame>On days 1 and 8 of each cycle, and up to 2 years after registration.</time_frame>
    <description>Defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during the study (having been absent at baseline) or if present at baseline, appears to worsen. Graded using scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Tabulated by type and severity: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Expression or Activation of One Biomarker With Another, With Biochemical and Clinical Responses, With Alterations in Cell Proliferation and Apoptotic Markers, and With Time to Progression</measure>
    <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
    <description>Changes in the ratio of phospho-S6Kinase (pS6K) S240/244 to total S6, in the tumor, from day 1 to day 23. These were assessed by reverse-phase protein array. A linear model was fit with PROC MIXED in SAS 9.3 using the log base 10 of expression as the outcome measure. This measure type is not listed in the data table form; so the number of patients who had decreases in that ratio is listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Biomarkers to Antitumor Activity/Patient Outcomes</measure>
    <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
    <description>Assessed in both tumor tissue pretreatment. Mutations in BRAF were assessed in all 16 of the patients and were assessed for any association with clinical response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Pre- vs Post-treatment Measurements of Biomarkers and Vascular System/Immune System Parameters</measure>
    <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
    <description>Biomarker expression in tumor and normal skin will be assessed by immunohistochemistry (IHC) or Western blotting, using marker-specific antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Day 11 of courses 4, 8, 12, 16, 20, and 24, and then annually for up to 5 years</time_frame>
    <description>Defined as the duration of time from start of treatment to time of progression, death or date of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IIIB Skin Melanoma</condition>
  <condition>Stage IIIC Skin Melanoma</condition>
  <condition>Stage IV Skin Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor, monoclonal antibody)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor, monoclonal antibody)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor, monoclonal antibody)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor, monoclonal antibody)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>CCI-779 Rapamycin Analog</other_name>
    <other_name>Cell Cycle Inhibitor 779</other_name>
    <other_name>Rapamycin Analog</other_name>
    <other_name>Rapamycin Analog CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo tumor resection</description>
    <arm_group_label>Treatment (enzyme inhibitor, monoclonal antibody)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed melanoma

               -  Stage III or IV disease

                    -  Recurrent disease allowed

          -  Measurable disease defined as ≥ 1 lesion that can be accurately measured in ≥ 1
             dimension as ≥ 20 mm with conventional techniques OR ≥ 10 mm with spiral CT scan

               -  Tumor lesions in previously irradiated areas are not considered measurable
                  disease

          -  Prior brain metastases allowed provided all of the following criteria are met:

               -  No more than a total of 5 brain metastases

               -  All metastases are no more than 2.5 cm

               -  Surgically resected or have been treated with gamma-knife or stereotactic
                  radiosurgery

               -  More than 30 days since prior disease progression

               -  More than 30 days since prior steroids for managing brain metastases

                    -  Concurrent steroids for other reasons allowed provided the dose is &lt; that
                       required for managing brain metastases

          -  Disease accessible for core needle biopsy, incisional biopsy, and/or surgical
             resection and meets one of the following criteria:

               -  One large tumor deposit ≥ 5 cm³ from which biopsies can be harvested multiple
                  times

               -  Multiple deposits that can be biopsied or excised individually on different
                  dates, measured as follows:

                    -  One lesion ≥ 5 cm^3

                    -  Two lesions ≥ 3 cm^3

                    -  Three lesions ≥ 2 cm^3

          -  ECOG performance status 0-1

          -  Weight ≥ 110 pounds (without clothes)

          -  WBC ≥ 3,000 mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin normal

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  Urine protein: creatinine ratio &lt; 1.0 OR 24-hour urine protein &lt; 1,000 mg

          -  Fasting cholesterol &lt; 350 mg/dL (cholesterol medications are allowed)

          -  Fasting triglycerides &lt; 400 mg/dL

          -  PT INR ≤ 1.5 (unless on full-dose anticoagulants)

          -  Hematocrit &lt; 41% (for males) or &lt; 38% (for females)

          -  None of the following within the past 4 weeks:

               -  Uncontrolled intercurrent illness

               -  Ongoing or active acute (CTCAE v.3 grade 3 or 4) infection

               -  Abdominal fistula

               -  Gastrointestinal perforation

               -  Intra-abdominal abscess

               -  Serious or nonhealing wound, ulcer, or bone fracture

          -  No psychiatric illness or social situations that would preclude study compliance

          -  No clinically significant cardiovascular disease, including the following:

               -  Cerebrovascular accident within the past 6 months

               -  Transient ischemic attack within the past 6 months

               -  Myocardial ischemia within the past 6 months

               -  Myocardial infarction within the past 6 months

               -  Other thromboembolic event within the past 6 months

               -  Unstable angina within the past 6 months

               -  Uncontrolled hypertension (i.e., hypertension despite maximal therapy)

               -  New York Heart Association class II-IV heart disease

               -  Congestive heart failure

               -  Serious cardiac arrhythmia requiring medication

               -  Clinically significant peripheral vascular disease

               -  History of stroke

               -  Artificial valve, pacemaker, or similar device

          -  No uncontrolled diabetes

               -  Hemoglobin A1c &lt; 7%

          -  No significant traumatic injury within the past 28 days

          -  No history of allergic reactions to compounds of similar chemical or biological
             composition to temsirolimus or bevacizumab

          -  No hypersensitivity to Chinese hamster ovary cell products or other recombinant human
             antibodies (e.g., infliximab)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study treatment

          -  HIV negative

          -  Hepatitis C negative

          -  See Disease Characteristics

          -  More than 4 weeks since any of the following prior treatments and recovered:

               -  Chemotherapy (6 weeks for nitrosoureas or mitomycin C)

               -  Radiotherapy to nontarget lesions or lesions that are not to be biopsied

               -  Immunotherapy

               -  Cytokine therapy

               -  Enzyme-inducing antiepileptic drugs (EIAEDs) or other CYP3A4 inducers

               -  Investigational agents

          -  More than 4 weeks since prior major surgery or open biopsy and recovered

          -  No prior temsirolimus, rapamycin, bevacizumab, or systemic therapies targeted
             primarily to vascular endothelial growth factor (VEGF), VEGF receptors, or to mTOR
             inhibition

          -  Concurrent full-dose anticoagulants (e.g., warfarin/low molecular weight heparin) with
             PT INR &gt; 1.5 are allowed provided the following criteria are met:

               -  In-range INR (usually between 2 and 3.5) on a stable dose of oral anticoagulant
                  or on a stable dose of low molecular weight heparin

               -  No active, clinically significant bleeding or pathological condition that carries
                  a high risk of bleeding (e.g., tumor involving major vessels or known varices)

                    -  Minimal tumor bleeding of the skin allowed at the clinician's discretion

          -  No concurrent medications or substances known to affect or with the potential to
             affect the activity or pharmacokinetics of the following:

               -  Temsirolimus

               -  Bevacizumab

               -  CYP450 isoenzymes

          -  No concurrent nonstudy-related surgical procedures

          -  No other concurrent anticancer agents or therapies

        Exclusion Criteria

          -  Participants who have received these medications or treatments at any time ≤ 4 weeks
             of registration:

               -  Chemotherapy

               -  Radiotherapy to non-target lesions and lesions that are not to be biopsied. Prior
                  radiotherapy to target lesions or lesions to be biopsied/resected is not
                  permitted

               -  Immunotherapy

               -  Cytokine therapy

               -  Investigational reagents

               -  Invasive procedures defined as follows:

                    -  Major surgical procedure, open biopsy or significant traumatic injury

                    -  Anticipation of need for non-study related surgical procedures from
                       registration until Cycle 26 (One year).

               -  Enzyme-inducing antiepileptic drugs (EIAEDs) or any other CYP3A4 inducer
                  (Appendix C).

        OR Participants who have not recovered from adverse events resulting from the
        administration of these agents/procedures &gt; 4 weeks prior to registration.

          -  Participants who have received nitrosureas or mitomycin C ≤ 6 weeks of registration.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to CCI-779 or bevacizumab, or with known hypersensitivity to Chinese
             hamster ovary cell products (t-PA) or other recombinant human antibodies (e.g.,
             Remicade®).

          -  Participants who have previously received CCI-779, rapamycin, bevacizumab, or systemic
             therapies targeted primarily to VEGF, VEGF receptors, or to mTOR inhibition.

          -  Participants who have experienced any of the following ≤ 4 weeks prior to
             registration:

               -  Uncontrolled intercurrent illness

               -  Infection, CTCAE3 grade 3 or 4 (either ongoing, chronic, or active infection)

               -  Abdominal fistula

               -  Gastrointestinal perforation

               -  Intra-abdominal abscess

               -  Serious or non-healing wound

               -  Serious or non-healing ulcer

               -  Serious or non-healing bone fracture.

          -  Potential subjects with clinically significant cardiovascular disease

               -  Recent history (defined as ≤ 6 months of registration) of thromboembolic events
                  including cerebrovascular accident (CVA), transient ischemic attack (TIA),
                  myocardial ischemia, myocardial infarction (MI)

               -  Uncontrolled hypertension (hypertension despite maximal therapy)

               -  Unstable angina ≤ 6 months of registration

               -  New York Heart Association Classification of ≥ class II heart disease

               -  Congestive heart failure

               -  Serious cardiac arrhythmia requiring medication

               -  Clinically significant peripheral vascular disease

               -  Have a history of stroke

               -  Have an artificial valve, pace-maker, or similar device

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Pregnant (positive pregnancy test) or nursing women. Both fertile men and women must
             agree to use adequate contraceptive measures during study therapy and for at least 6
             months after the completion of their participation in the study therapy.

          -  PT INR &gt; 1.5, (unless the potential subject is on full dose anticoagulants and meet
             criteria described in Section 3.1.8).

          -  Participants with uncontrolled diabetes, defined as having a HGBA1C ≥ 7%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Slingluff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Slingluff CL Jr, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 1;19(13):3611-20. doi: 10.1158/1078-0432.CCR-12-3919. Epub 2013 Apr 25.</citation>
    <PMID>23620404</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagenseller AG, Shada A, D'Auria KM, Murphy C, Sun D, Molhoek KR, Papin JA, Dutta A, Slingluff CL Jr. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med. 2013 Sep 18;11:218. doi: 10.1186/1479-5876-11-218.</citation>
    <PMID>24047116</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2017</results_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment from Jan 2008 - Feb 2011 at the University of Virginia Cancer Center and Fox Chase Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Enzyme Inhibitor, Monoclonal Antibody)</title>
          <description>Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
Bevacizumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
Temsirolimus: Given IV
Therapeutic Conventional Surgery: Undergo tumor resection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated health issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study</title>
          <description>Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
Bevacizumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
Temsirolimus: Given IV
Therapeutic Conventional Surgery: Undergo tumor resection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and Bevacizumab</title>
        <description>Evaluated using Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
        <time_frame>Up to 18 weeks after registration.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and Bevacizumab</title>
          <description>Evaluated using Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events in Participants With Stage III or IV Melanoma Treated With Temsirolimus and Bevacizumab</title>
        <description>Defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during the study (having been absent at baseline) or if present at baseline, appears to worsen. Graded using scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Tabulated by type and severity: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
        <time_frame>On days 1 and 8 of each cycle, and up to 2 years after registration.</time_frame>
        <population>Treatment related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>17 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events in Participants With Stage III or IV Melanoma Treated With Temsirolimus and Bevacizumab</title>
          <description>Defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during the study (having been absent at baseline) or if present at baseline, appears to worsen. Graded using scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Tabulated by type and severity: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.</description>
          <population>Treatment related adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>grade 3 hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 3 weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 4 lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>grade 2 leukoencephalopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Expression or Activation of One Biomarker With Another, With Biochemical and Clinical Responses, With Alterations in Cell Proliferation and Apoptotic Markers, and With Time to Progression</title>
        <description>Changes in the ratio of phospho-S6Kinase (pS6K) S240/244 to total S6, in the tumor, from day 1 to day 23. These were assessed by reverse-phase protein array. A linear model was fit with PROC MIXED in SAS 9.3 using the log base 10 of expression as the outcome measure. This measure type is not listed in the data table form; so the number of patients who had decreases in that ratio is listed.</description>
        <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
        <population>This analysis was performed for those participants with sufficient tumor available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>17 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Expression or Activation of One Biomarker With Another, With Biochemical and Clinical Responses, With Alterations in Cell Proliferation and Apoptotic Markers, and With Time to Progression</title>
          <description>Changes in the ratio of phospho-S6Kinase (pS6K) S240/244 to total S6, in the tumor, from day 1 to day 23. These were assessed by reverse-phase protein array. A linear model was fit with PROC MIXED in SAS 9.3 using the log base 10 of expression as the outcome measure. This measure type is not listed in the data table form; so the number of patients who had decreases in that ratio is listed.</description>
          <population>This analysis was performed for those participants with sufficient tumor available for analysis.</population>
          <units>participants who had decreases in ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Biomarkers to Antitumor Activity/Patient Outcomes</title>
        <description>Assessed in both tumor tissue pretreatment. Mutations in BRAF were assessed in all 16 of the patients and were assessed for any association with clinical response</description>
        <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
        <population>Patients evaluable for clinical outcome with BRAF mutation status.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>17 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Biomarkers to Antitumor Activity/Patient Outcomes</title>
          <description>Assessed in both tumor tissue pretreatment. Mutations in BRAF were assessed in all 16 of the patients and were assessed for any association with clinical response</description>
          <population>Patients evaluable for clinical outcome with BRAF mutation status.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BRAF-wild type</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Partial responses</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease at 8 wks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAF-mutant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Partial responses</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease at 8 wks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Pre- vs Post-treatment Measurements of Biomarkers and Vascular System/Immune System Parameters</title>
        <description>Biomarker expression in tumor and normal skin will be assessed by immunohistochemistry (IHC) or Western blotting, using marker-specific antibodies.</description>
        <time_frame>Day 1 of course 1 and day 8 of course 2</time_frame>
        <population>Detailed vascular changes were not assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>17 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Pre- vs Post-treatment Measurements of Biomarkers and Vascular System/Immune System Parameters</title>
          <description>Biomarker expression in tumor and normal skin will be assessed by immunohistochemistry (IHC) or Western blotting, using marker-specific antibodies.</description>
          <population>Detailed vascular changes were not assessed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Defined as the duration of time from start of treatment to time of progression, death or date of last follow-up.</description>
        <time_frame>Day 11 of courses 4, 8, 12, 16, 20, and 24, and then annually for up to 5 years</time_frame>
        <population>Entire study</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study</title>
            <description>17 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Defined as the duration of time from start of treatment to time of progression, death or date of last follow-up.</description>
          <population>Entire study</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="1.1" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 years after registration</time_frame>
      <desc>CTCAE 3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Entire Study</title>
          <description>Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
Bevacizumab: Given IV
Laboratory Biomarker Analysis: Correlative studies
Temsirolimus: Given IV
Therapeutic Conventional Surgery: Undergo tumor resection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphopenia</sub_title>
                <description>grade 4 lymphopenia, both were evident pre-treatment at grade 1 and grade 3 for the two patients, respectively.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <description>grade 3 lymphopenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>grade 3 anemia (hemoglobin)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>low CD4 count</sub_title>
                <description>grade 3 decrease in CD4 counts</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>grade 3 hypertension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis (funct/sympt) - Oral cavity</sub_title>
                <description>grade 3 mucositis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>grade 3 nausea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <description>grade 3 anorexia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <description>grade 3 pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <description>grade 3 headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <description>grade 3 weight loss</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <description>grade 2 leukoencephalopathy, reversible.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Lymphopenia in 5 patients (1 grade 1, 3 grade 2, 1 grade 3), not including the 2 patients with lymphopenia SAEs.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hemorrhage / Bleeding</sub_title>
                <description>7 grade 1, 1 grade 2.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Edema - limb</sub_title>
                <description>Edema: 1 grade 1, 2 grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hemorrhage - lung</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hemorrhage - rectal</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Edema - head and neck</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <description>low hemoglobin: 8 grade 1, 5 grade 2, in addition to the one grade 3 SAE</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Platelets (thrombocytopenia)</sub_title>
                <description>11 grade 1, 3 grade 2</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <description>4 grade 1, 2 grade 2</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <description>3 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension, 1 grade 2. This is in addition to the 1 grade 3 SAE.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>hypotension: 3 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>3 grade 1, 5 grade 2</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis - funct/sympt oral</sub_title>
                <description>4 grade 1, 3 grade 2, in addition to 1 grade 3 SAE</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>7 grade 1, 2 grade 2, in addition to the one grade 3 SAE.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>10 grade 1, 2 grade 2, in addition to 1 grade 3 SAE.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>4 grade 1, 1 grade 1</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>mucositis - larynx</sub_title>
                <description>3 grade 1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>mucositis - esophagus</sub_title>
                <description>1 grade 1.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>GI - other</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - anus</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - stomach</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - abdomen NOS</sub_title>
                <description>2 grade 1, 1 grade 2, in addition to the one grade 3 SAE</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>6 grade 1, 4 grade 2</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>mucositis - clinical exam - oral</sub_title>
                <description>7 grade 1, 3 grade 2</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <description>10 grade 1</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>6 grade 1</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>6 grade 1, 5 grade 2.</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever: 3 grade 1, 3 grade 2</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <description>8 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>1 grade 1.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>4 grade 1, 5 grade 2, plus 2 wt loss SAEs.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>flu-like syndrome</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <description>6 grade 1</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>grade 1 rhinitis: 1 patient</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, normal ANC, abdomen</sub_title>
                <description>1 grade 2.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infection, normal ANC, oral cavity</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infection (other)</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>3 grade 2, in addition to 2 grade 3 (SAE)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>3 grade 1, in addition to 2 grade 3 SAEs</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>4 grade 1, 3 grade 2.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <description>8 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <description>Elevated AST: 7 grade 1, 1 grade 2.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <description>Elevated alkaline phosphatase: 4 grade 1, 1 grade 2.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <description>3 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <description>Elevated creatinine: 2 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>1 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cholesterol</sub_title>
                <description>Increased cholesterol: 10 grade 1</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>low serum bicarbonate</sub_title>
                <description>grade 1: 7</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <description>Elevated ALT: 4 grade 1</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <description>2 grade 1.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>acidosis</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hemoglobinuria</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>4 grade 1</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - extremity</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <description>1 grade 1, muscle weakness, lower extremity</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain - tumor</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - headache</sub_title>
                <description>seven grade 1, in addition to the one grade 3 SAE.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <description>2 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <description>one grade 1 urinary frequency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis - vaginal</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>3 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pulmonary - other</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - oral cavity</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>2 grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - chest wall</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - oral - gums</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>pain - throat</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>5 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>nasal/paranasal reactions</sub_title>
                <description>3 grade 1</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis/itching</sub_title>
                <description>6 grade 1 , 2 grade 2</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <description>rash: 12 grade 1, 1 grade 2.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <description>1 grade 1, 1 grade 2</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>12 grade 1 only.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash - acneiform</sub_title>
                <description>6 grade 1 only.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Wound complications, non-infectious</sub_title>
                <description>4 grade 1.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hair loss / alopecia</sub_title>
                <description>3 grade 1.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dermatology - other</sub_title>
                <description>1 grade 1.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - scalp</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain - skin</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <description>1 grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>hypopigmentation - skin</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <description>1 grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Slingluff</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434 924 1730</phone>
      <email>cls8h@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

